44 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 44 of 44 clinical reviews.
Complete guide to Aetna (CVS Health) coverage of liraglutide for weight loss and type 2 diabetes, including prior authorization criteria, step therapy requirements, formulary placement, and how to appeal a denial.
Find out if Anthem (Elevance Health) covers liraglutide for weight loss or type 2 diabetes, including prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial.
A clinical and insurance guide to Blue Cross Blue Shield (Federated) coverage of liraglutide for weight loss and type 2 diabetes, including prior authorization, step therapy, formulary tier, and appeal strategies.
A complete guide to Cigna coverage for liraglutide (Victoza, Saxenda), including prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A clinical and coverage guide to liraglutide on Kaiser Permanente plans: formulary tier, prior authorization criteria, step-therapy requirements, appeal pathways, and cost options for 2024.
Evidence-based guide to tapering and discontinuing liraglutide (Saxenda/Victoza generics) safely, including step-down schedules, rebound weight gain prevention, and metabolic monitoring.
Evidence-based liraglutide dosing guide for adults aged 30, 49, covering the 5-week escalation schedule, 3.0 mg maintenance dose, injection technique, and clinical considerations specific to this age group.
A complete clinical guide to monitoring liraglutide in adults aged 30 to 49, covering labs, vitals, GI tolerance, dose titration checkpoints, and red-flag signs that require urgent review.
A breakdown of liraglutide pricing, mechanism, and how it compares to semaglutide, dulaglutide, and tirzepatide on cost, efficacy, and dosing convenience.
How liraglutide is dosed and titrated in adults ages 50 to 64, including the FDA-approved titration schedule, cardiovascular and renal considerations, polypharmacy risks, and where trial evidence does and does not directly speak to this age group.
How to dose liraglutide (Saxenda, Victoza, generics) in patients with mild, moderate, or severe hepatic impairment. FDA label guidance, pharmacokinetic data, NAFLD/NASH considerations, and monitoring recommendations.
Evidence-based guide to liraglutide dosing in patients with renal impairment, including CKD stages 3-5 and dialysis considerations, drawn from FDA labeling and the pharmacokinetic and outcomes literature.
Evidence-based guide to liraglutide drug-drug interactions covering insulin, sulfonylureas, oral contraceptives, warfarin, acetaminophen, and more. PubMed-cited.
A guide to liraglutide food and supplement interactions, covering how the drug works, which foods and supplements plausibly alter absorption or glycemic response, and practical timing strategies for patients on Victoza or Saxenda.
A comprehensive clinical review of liraglutide for metabolic syndrome, covering FDA approval status, SCALE trial evidence, dosing protocols, side-effect management, and coverage options for patients with the condition.
A guide to liraglutide for NAFLD and MASLD, covering trial evidence, dosing protocols, side effects, and how it compares to newer GLP-1 agents and resmetirom.
A guide to using liraglutide for prediabetes, covering SCALE trial evidence, dosing protocols, side effects, and who qualifies for treatment.
A guide to liraglutide for type 2 diabetes covering FDA approval, LEADER trial outcomes, HbA1c reduction data, dosing schedules, side effects, and practical prescribing guidance.
A clinical review of liraglutide's upcoming formulations, generic entries, oral alternatives, and combination therapies in development, with trial data and FDA timeline estimates.
A guide to liraglutide dosing in adults 65 and older, covering titration schedules, renal and hepatic adjustments, fall risk, polypharmacy, and deprescribing.
Complete guide to monitoring liraglutide in patients aged 65 and older, covering renal function, falls risk, drug interactions, deprescribing, and dose titration based on SCALE trial data and current guidelines.
Evidence-based guide to liraglutide safety in adults 65 and older, covering renal considerations, fall risk, drug interactions, GI side effects, and geriatric-specific monitoring.
A clinical deep-dive into how liraglutide was developed, its mechanism of action, key trials like SCALE and LEADER, FDA approvals, and what the arrival of generic versions means for patients.
Evidence-based guide to liraglutide use in transplant recipients, people living with HIV, and other special populations. Covers dosing, safety signals, drug interactions, and clinical trial data.
A clinical deep-dive into liraglutide's manufacturing process, supply chain history, FDA shortage events, and what prescribers and patients should know about current availability.
A physician-level breakdown of how liraglutide works, from GLP-1 receptor binding and cAMP signaling to appetite suppression, gastric slowing, and beta-cell preservation.
Evidence-based guide to managing missed liraglutide doses, including timing windows, re-titration rules, and clinical recommendations for both Saxenda and Victoza users.
Evidence-based monitoring guide for adults aged 50-64 taking liraglutide. Covers baseline labs, renal function tracking, cardiovascular risk panels, GI safety, and dose-titration checkpoints.
Evidence-based liraglutide monitoring schedule covering baseline labs, ongoing bloodwork, renal panels, thyroid surveillance, and clinical exams required during GLP-1 therapy.
A clinician-level review of liraglutide off-label uses, ranked by evidence strength, with mechanism of action, dosing, and PubMed-cited trial data.
Evidence-based guide to liraglutide overdose management, covering symptoms of accidental excess dosing, hypoglycemia risk, clinical monitoring protocols, and when to seek emergency care.
A breakdown of liraglutide's patent expiration dates, generic entry timeline, biosimilar regulatory pathway, mechanism of action, and clinical evidence from SCALE Obesity and LEADER trials.
A clinician-level review of how GLP1R, TCF7L2, FTO, and other genetic variants shape liraglutide efficacy, side-effect risk, and dosing strategy in type 2 diabetes and chronic weight management.
A clinician-grade breakdown of liraglutide pharmacokinetics covering subcutaneous absorption, albumin binding, DPP-4-like metabolism, half-life, and dosing implications for weight management and type 2 diabetes.
Evidence-based review of liraglutide (Saxenda/Victoza) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and clinical guidance for women of reproductive age.
A clinical review of liraglutide real-world evidence from registries, electronic health records, and observational studies, comparing RWE outcomes to randomized trial results for weight loss and type 2 diabetes.
A guide to liraglutide's regulatory status across the US, EU, Canada, and UK, covering how liraglutide works, approved indications, dosing, and the current state of generic and biosimilar development.
A clinical review of liraglutide safety data specific to adults aged 30-49, covering GI side effects, pancreatitis risk, thyroid signals, cardiovascular outcomes, and monitoring protocols.
A clinically detailed review of liraglutide safety for adults ages 50 to 64, covering cardiovascular outcomes, GI tolerability, hypoglycemia risk, polypharmacy interactions, and perimenopause or andropause overlap. Based on SCALE Obesity, LEADER, and current ADA and Endocrine Society guidelines.
A clinical review of liraglutide safety data specific to young adults aged 18 to 29, covering adverse effects, fertility considerations, cardiovascular outcomes, and monitoring protocols.
A clinical review of every major liraglutide safety signal, FDA warning, and post-marketing action from 2010 through 2026, with cited trial data and regulatory source documents.
A guide to liraglutide self-injection technique, including site selection, dose titration, needle handling, and troubleshooting common errors.
How to store liraglutide pens before and after first use, temperature excursion limits, and expiration timelines backed by FDA labeling and stability data.
Evidence-based protocols for switching between liraglutide and other GLP-1 receptor agonists including semaglutide and tirzepatide, with dose-titration schedules, clinical data, and safety considerations.